Major Successes of Eli Lilly and Regeneron in Gene Therapy Discoveries
Thursday, 16 May 2024, 11:15
Challenges in Restoring Hearing
Eli Lilly and Regeneron are targeting deafness caused by variations in the otoferlin gene, crucial for proper hearing. Children affected by this defect often have limited treatment options. Eli Lilly's gene therapy, AK-OTOF, showed impressive results in restoring hearing for an 11-year-old patient within 30 days.
The Therapeutic Advances
- Regeneron's gene therapy, DB-OTO, demonstrated hearing improvements in patients dosed at different ages.
- Both companies exhibit significant potential in the hearing loss market with their pioneering therapies.
Investing wisely in these innovative companies can lead to long-term growth and success.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.